The Nomination Committee of Oasmia propose changes in the company´s Board of Directors to be decided on an Extraordinary General Meeting (EGM) to be held on May 14, 2020. Current board member Anders Härfstrand is proposed to be the new Chairman of the Board and Birgit Stattin Norinder is suggested to be a new member of the Board. Jörgen Olsson, current Chairman of the Board, and Gunilla Öhman, current Board member, will leave the Board.
“Oasmia has had an eventful year with first sorting out issues of the past and then successfully pursuing a rights issue and entering into a global partnership. This has required intense work by the Board. Now entering the next step in the company’s development, a switch to more pharma industry competence on the Board is desirable. The contribution from Jörgen Olsson and Gunilla Öhman during this past year, with vast competence of company turn-arounds, troubleshooting and transparent communication, has been extraordinary. However, we see no point in awaiting an AGM for this change. With Birgit Stattin Norinder on the Board we will add further life science expertise and industry network”, says Per Arwidsson, chairman of the Nomination Committee and major shareholder of Oasmia through Arwidsro.
The current Nomination Committee consists of the three representatives; Per Arwidsson, Arwidsro, Chairman of the Nomination Committee, Håkan Lagerberg and Jörgen Olsson, current Chairman of the Board. Jörgen Olsson is suggested to be replaced in the Nomination Committee by Anders Härfstrand.
The EGM is to be held on May 14, 2020. A detailed notice to the EGM will be published separately by the company today.
About Birgit Stattin Norinder
Birgit Stattin Norinder has extensive experience from international pharmaceutical and biotechnology companies in Sweden, the USA and Europe. She has managed several research and development departments, resulting in a number of novel and approved pharmaceuticals. Amongst many things she has served as CEO and Chairman at Prolifix Ltd., Senior VP Worldwide Product Development, Pharmacia & Upjohn and Dir. Int. Reg. Affairs Division, Glaxo Group Research Ltd. She was Chairman of the Board of Hansa Biopharma 2014-2016, member of the board of Nicox S.A, WNTresearch AB, Karo Bio AB, Prolifix Ltd and she is currently a member of the board of Hansa Biopharma AB, AddLife AB and Jettesta AB. Birgit Stattin Norinder holds an M.Sc. in Pharmacy from Uppsala University. She was born in 1948.
For more information:
IR Manager Oasmia
Phone: +46 18-50 54 40
E-mail: IR@oasmia.com 
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures and markets new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on Nasdaq Stockholm (OASM) and Frankfurt Stock Exchange (OMAX.GR).
This information is information that Oasmia Pharmaceutical is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2020-04-17 10:15 CEST.